Does Christiana Care Health System Cover Vyvanse?

What ChristianaCare Actually Controls Regarding Prescription Coverage

ChristianaCare is a nonprofit health system headquartered in Newark, Delaware. It employs clinicians, operates hospitals, and offers an employee benefits program, but it is not a pharmacy benefits manager (PBM) and does not independently decide which drugs are covered under most patients' insurance plans. Whether Vyvanse is covered for a given patient depends on the insurer or PBM managing that patient's pharmacy benefit.

The Three Coverage Pathways at ChristianaCare

1. ChristianaCare Employee Health Plan. Employees of ChristianaCare itself receive benefits through a self-funded employer plan administered by a third-party insurer. As of 2024, that plan's formulary and prior-authorization rules are set annually and may differ from public commercial products.

2. Commercial insurance accepted at ChristianaCare clinics. Aetna, Highmark, Cigna, UnitedHealthcare, and other major carriers all contract with ChristianaCare. Each carrier maintains its own formulary. Vyvanse appears on many commercial formularies at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), triggering copays that range from $60 to $150 per fill after the deductible.

3. Delaware Medicaid (Diamond State Health Plan). Delaware Medicaid is administered through managed-care organizations (MCOs) including Highmark Delaware, Aetna Better Health of Delaware, and Molina Healthcare. Each MCO publishes its own preferred drug list (PDL). Medicaid PDLs in Delaware list amphetamine salts and methylphenidate products as first-line; Vyvanse typically requires prior authorization and documented failure of at least one first-line agent.

Why the Distinction Matters

Patients often ask their ChristianaCare provider "will this be covered?" The honest answer is that the provider can submit a prior-authorization request, but the coverage decision is made by the payer, not by the health system. Knowing which payer holds your pharmacy benefit is the first practical step.

Vyvanse: FDA Approval, Mechanism, and Clinical Evidence

Vyvanse (lisdexamfetamine dimesylate) received FDA approval for ADHD in adults in 2008 and for children aged 6 to 17 in 2007 [1]. In 2015 it received an additional approval for moderate-to-severe binge eating disorder (BED) in adults [2]. It is a prodrug: lisdexamfetamine is pharmacologically inactive until cleaved by red-blood-cell enzymes to release d-amphetamine, which increases synaptic dopamine and norepinephrine.

Efficacy Data for ADHD

The key trial supporting adult ADHD approval (Study SPD489-325, N=420) showed statistically significant reductions in ADHD-RS-IV total score versus placebo at all doses tested (30 mg, 50 mg, 70 mg), with a mean treatment difference of 8.0 to 11.7 points (P<0.001) [3]. A 2018 Cochrane systematic review of 21 randomized controlled trials covering 2,017 participants confirmed lisdexamfetamine outperforms placebo on clinician-rated ADHD symptom scales (standardized mean difference 0.79, 95% CI 0.64 to 0.93) [4].

Efficacy Data for Binge Eating Disorder

In the key Phase III BED trials (N=724 combined across two studies), lisdexamfetamine 50 mg and 70 mg significantly reduced binge-eating days per week versus placebo, with 50 mg producing a mean reduction of 3.87 binge-eating days per week compared with 2.51 for placebo (P<0.001) [5].

Safety Profile Relevant to PA Documentation

Common adverse effects include decreased appetite, insomnia, dry mouth, and elevated heart rate. The FDA label carries a black-box warning regarding the potential for abuse and dependence [6]. Prescribers documenting a PA request must typically confirm cardiovascular screening, absence of active substance use disorder, and documented ADHD diagnosis using a validated tool such as the Adult ADHD Self-Report Scale (ASRS-v1.1) or Conners' Rating Scales in pediatric patients.

Prior Authorization for Vyvanse: What ChristianaCare Prescribers Submit

Prior authorization (PA) is a formal insurer review that determines whether a drug is medically necessary before the plan will pay for it. The American Academy of Family Physicians has described PA as one of the primary administrative burdens reducing time clinicians spend with patients [7]. For Vyvanse specifically, PA criteria across most commercial plans include several standard elements.

Standard PA Criteria

Most plans require:

• A confirmed ADHD or BED diagnosis coded to ICD-10 F90.x (ADHD) or F50.81 (Binge Eating Disorder)
• Age-appropriate diagnostic workup (DSM-5 criteria, validated rating scales, symptom duration of at least 6 months with onset before age 12 for ADHD)
• Documentation of at least one trial of a first-line agent (methylphenidate or mixed amphetamine salts) of adequate dose and duration, with specific reason for discontinuation or inadequate response
• Absence of contraindications listed in the Vyvanse FDA prescribing information [6]
• For BED, documentation that behavioral interventions were attempted

Timeline and Practical Steps

After a ChristianaCare clinician submits the PA, most plans must respond within 3 business days for urgent requests and 14 calendar days for standard requests under federal and state managed-care regulations. Delaware Medicaid MCOs are bound by DHSS contract standards that mirror federal 42 CFR 438.210 timelines [8].

If the PA is denied, the prescriber has the right to request a peer-to-peer review with the plan's medical director. In Delaware, insurers regulated under Title 18 of the Delaware Insurance Code must provide an internal appeal process and, if that fails, access to an external independent review.

HealthRX Prior-Authorization Decision Framework for Vyvanse at ChristianaCare Network Practices

| Step | Action | Who Does It | Typical Timeframe | |---|---|---|---| | 1 | Confirm ICD-10 diagnosis in chart | Prescriber | At visit | | 2 | Document first-line trial (if applicable) | Prescriber | At visit | | 3 | Submit PA with clinical notes to plan | Office staff / ePA system | Same day | | 4 | Plan review period | Insurer | 3 to 14 days | | 5 | Approval: send e-prescription | Prescriber | Immediate | | 6 | Denial: request peer-to-peer within 5 days | Prescriber | 24 to 48 hours | | 7 | Uphold denial: file formal appeal with supporting literature | Office staff | 10 to 30 days | | 8 | External independent review if needed | Third-party IRO | 30 to 45 days |

ADHD Diagnosis Standards That Support a Successful PA

A valid prior-authorization request rests on a well-documented ADHD diagnosis. The DSM-5 requires at least six inattentive or hyperactive-impulsive symptoms in adults (five for those aged 17 and older), present for at least 6 months, impairing in two or more settings, with symptom onset before age 12 [9].

Validated Diagnostic Tools

The ASRS-v1.1 (Adult ADHD Self-Report Scale), developed with the World Health Organization, has a sensitivity of 68.7% and specificity of 99.5% for DSM-IV ADHD in community samples [10]. Many ChristianaCare behavioral health and primary care providers use it as a screening adjunct before full diagnostic evaluation. For children, the Conners' 3 rating scale provides teacher and parent versions with age-normed T-scores.

Why Documentation Quality Affects Coverage

Insurers deny PA requests more often when chart notes lack explicit DSM-5 symptom counts, rating-scale scores, or functional impairment documentation across settings. The 2022 APA Practice Guideline for ADHD recommends that clinicians include both a clinician-administered interview and validated self-report data in diagnostic records [9]. Including that documentation in the PA packet reduces denial rates in practice.

What Happens When Coverage Is Denied

A denial is not a final answer. Federal law under the ACA and Delaware state insurance regulations give patients and providers structured appeal rights.

Internal Appeal

The insurer must conduct an internal appeal review within 30 days for pre-service denials. The prescriber should submit peer-reviewed literature supporting medical necessity, including the Cochrane meta-analysis referenced above [4] and the FDA-approved prescribing information [6].

External Independent Review

If the internal appeal is upheld, the patient may request external review through the Delaware Department of Insurance. Independent review organizations (IROs) overturn insurer denials roughly 40% of the time for prescription drug coverage disputes, based on aggregate data from state insurance commissioner reports.

Exceptions Process

Some plans offer a formulary exception process separate from the clinical PA. If a generic alternative is on formulary but causes documented adverse effects, the prescriber can request a formulary exception to cover the brand at a lower cost-share.

Cost of Vyvanse Without Insurance or After Denial

Cash prices for Vyvanse 70 mg (30 capsules) range from approximately $310 to $390 at major pharmacy chains as of early 2025. Generic lisdexamfetamine, approved by FDA in 2023 after patent litigation settled, carries a substantially lower cash price of roughly $80, $150 per 30-count fill depending on the pharmacy and dose.

Manufacturer Savings Programs

Takeda (Vyvanse's manufacturer) offers a savings card for commercially insured patients that may reduce out-of-pocket cost to as little as $30 per month. This card is not valid for Medicare, Medicaid, or other government-funded plans. Terms are updated annually at Takeda's patient support site.

GoodRx and Pharmacy Discount Programs

GoodRx and similar discount programs may reduce the cash price of generic lisdexamfetamine by 60 to 70% at participating pharmacies. A patient with a ChristianaCare prescription can use these programs at any network or out-of-network pharmacy; they are not insurance and do not require PA.

Patient Assistance Programs

Takeda's TAP (Takeda Assistance Program) provides Vyvanse at no cost to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). The application requires prescriber signature and income documentation.

Alternatives to Vyvanse That May Have Better Formulary Status

When Vyvanse is not covered or prior authorization is repeatedly denied, several alternatives share evidence for ADHD treatment.

Amphetamine-Based Alternatives

Mixed amphetamine salts (Adderall, generic available) are listed as preferred first-line on nearly all commercial and Medicaid formularies. A head-to-head network meta-analysis published in The Lancet Psychiatry (N=133 trials, 10,068 participants) ranked amphetamines as the most effective pharmacological treatment for ADHD in adults [11]. For patients who do not respond to immediate-release formulations, extended-release mixed amphetamine salts (Adderall XR, generic available) offer the same formulary advantages.

Methylphenidate-Based Alternatives

Concerta (methylphenidate extended-release) and its generics are Tier 1 or Tier 2 on most formularies. The same Lancet Psychiatry meta-analysis placed methylphenidate as the most effective first-line agent in children [11].

Non-Stimulant Options

Strattera (atomoxetine), Intuniv (guanfacine ER), and Kapvay (clonidine ER) are non-stimulant FDA-approved ADHD treatments with generally better formulary positioning. Atomoxetine carries a full FDA approval for adults and children aged 6 and older [12]. It is often preferred when there is a history of substance use disorder or when stimulants cause intolerable cardiovascular adverse effects.

How to Work With a ChristianaCare Provider to Maximize Approval Odds

ChristianaCare operates more than 50 outpatient practice sites across Delaware and the surrounding region. Primary care physicians, psychiatrists, and neurologists within the network are trained in ADHD evaluation and can initiate a Vyvanse PA.

Before the Appointment

Bring records of any previous ADHD evaluations, prior medication trials (including dose, duration, and reason for discontinuation), rating scale scores, and a list of current insurance cards. Most ChristianaCare practices use Epic as their electronic health record, and many have integrated ePA tools that submit directly to major PBMs.

At the Appointment

Ask the provider to document DSM-5 symptom criteria explicitly in the visit note, not just a diagnostic code. Ask for functional impairment examples across at least two settings (work/school and home). Request that the provider note the specific inadequacy of any previously tried medication, as this detail is the most common missing element in denied PA requests.

After the Appointment

If PA is approved, fill the prescription promptly. PA approvals typically authorize 12 months of coverage; the process must be repeated annually. If denied, contact the prescriber's office within 48 hours to initiate peer-to-peer review before the insurer's deadline passes.

Delaware Medicaid and Vyvanse: Specific Rules

Delaware Medicaid's preferred drug list (PDL) is published quarterly by DHSS and managed through the Diamond State Health Plan MCOs. As of the most recent published PDL cycle, Vyvanse is listed as non-preferred for ADHD with PA required. The PA criteria for Medicaid specifically include:

• Patient aged 6 or older (no off-label pediatric use below this age covered)
• Confirmed ADHD diagnosis per DSM-5
• Documented trial of at least one preferred stimulant (methylphenidate or amphetamine salt product) for a minimum of 4 weeks at an adequate dose
• Clinical documentation of inadequate response or intolerance

For BED in adults, Delaware Medicaid coverage of Vyvanse for BED requires separate prior authorization with documentation that the patient meets DSM-5 criteria for moderate-to-severe BED (8 or more binge episodes over the preceding 3 months) and that behavioral/dietary counseling has been attempted.

Delaware Medicaid recipients have the same appeal rights as commercial enrollees under 42 CFR 438.400 through 438.424, which govern managed-care grievance and appeal procedures [8].

Key Takeaway for Patients at ChristianaCare

Coverage for Vyvanse at ChristianaCare network practices flows entirely through the patient's insurer or Medicaid MCO. The health system's role is to provide the clinical documentation that supports the prior-authorization request. Patients who arrive with complete records, a clear prior-medication history, and validated rating-scale scores give their ChristianaCare prescriber the best chance of submitting a successful PA on the first attempt. If the first PA is denied, peer-to-peer review resolves roughly half of commercial-plan denials without a formal appeal. Generic lisdexamfetamine provides a lower-cost fallback when the brand remains uncovered after appeal. Confirm your specific plan's formulary tier and PA criteria by calling the member services number on the back of your insurance card before your appointment.